| BAC |
Report |
Diluted EPS |
BEAT |
pred ~$1.17 vs. cons $1.13 |
MEDIUM |
| BAC |
Report |
FTE net interest income |
BEAT |
pred ~$16.3B vs. cons $16.1B |
HIGH |
| BAC |
Report |
Sales and trading revenue ex-DVA |
BEAT |
pred ~$6.8B vs. cons $6.6B |
MEDIUM |
| BAC |
Guide |
FY2026 NII growth |
UNCHANGED |
guide ~7.0% vs. cons 7.0% (FY2026) |
HIGH |
| BAC |
Guide |
FY2026 positive operating leverage |
BETTER |
guide ~250 bps vs. cons 225 bps (FY2026) |
MEDIUM |
| BAC |
Guide |
FY2026 effective tax rate |
UNCHANGED |
guide ~20.5% vs. cons 20.5% (FY2026) |
HIGH |
| BAC |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| BAC |
Return |
5-day cumulative residual |
+0.5% (FADE) |
The reported beat is driven by ~$0.04 of EPS upside and ~$0.2B of NII upside, but retained ~7.0% FY2026 NII growth guidance versus ~7.0% consensus leaves little reason to lift FY2027 estimates. With the stock already priced for durable operating leverage, initial strength should fade as investors focus on unchanged out-period NII and funding-cost assumptions. |
MEDIUM |